Pathological Gambling Clinical Trial
— NalGambOfficial title:
Double-blind, Placebo-controlled Randomised Study on the Efficacy of Naloxone Nasal Spray for the Treatment of Gambling Disorder
Verified date | July 2019 |
Source | National Institute for Health and Welfare, Finland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary objective:
*To determine whether treatment with naloxone hydrochloride nasal spray reduces gambling urge
symptoms in patients with gambling disorder
The secondary objectives of the study are:
- To determine the effects of naloxone hydrochloride nasal spray on gambling severity,
frequency and time, internet use, self-efficacy, quality of life, alcohol consumption,
depression
- To evaluate the safety of naloxone hydrochloride nasal spray in the treatment of
gambling disorder
Status | Enrolling by invitation |
Enrollment | 126 |
Est. completion date | March 30, 2020 |
Est. primary completion date | August 30, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Inclusion criteria: The Subject must satisfy the following criteria for entry into the study: 1. Aged 18 to 75 years, fluent in Finnish and able to read and understand the patient information sheet 2. Provide written, informed consent prior to any study specific procedure being conducted 3. Gambling problem at pre-screening (SOGS 5 or more points) 4. Moderate (6-7 criteria met) or severe (8-9 criteria met) GD (DSM-5) assessed by clinical interview with Medical Doctor (MD) 5. At least 4 weeks since completion of any other previous treatment for GD 6. At least 8 weeks since completion of any previous treatment with naltrexone or nalmefene 7. Willingness to comply with all study procedures and visit schedules Exclusion Criteria: - Exclusion criteria: The Subject will be excluded from the study if any of the following applies: 1. Two weeks or longer abstinence from gambling prior to randomisation 2. Known allergic reactions to naloxone or excipients of IMP and placebo 3. Current use of drugs (opiates, amphetamine, metamphetamine, cocaine, cannabis and benzodiazepines) (as assessed by saliva drug screen, DrugWipe-6) 4. Subject is taking any prohibited medication (opioid analgesics, any medication delivered to the nose) 5. Serious mental illness or severe Depression assessed by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Disorders (SCID-I, DSM-5) and the Montgomery and Asberg Depression Rating Scale (MADRS) scores 24 points or more 6. Clinically significant risk of suicide (Columbia-Suicide Severity Rating Scale (C-SSRC)) 7. Women who are pregnant or breastfeeding at screening or Baseline 8. Serious kidney (P-Creatinine > 110 umol/ml) insufficiency 9. The Subject/patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason. 10. Liver cirrhosis or liver enzyme elevations, ASAT or ALAT >200 (by blood drop test), 11. Active HCV infection (saliva test, OralQuick-HCV) 12. The person that met the criteria of vulnerable person according to Finnish Medical Research Act No188/1999 7-10ยง 13. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless surgically sterile must use effective contraception (either combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD], intrauterine hormone-releasing system [IUS], vasectomised partner, sexual abstinence (only considered an acceptable method of contraception when it is in line with the subjects' usual and preferred lifestyle), combination of male condom with either cap, diaphragm or sponge with spermicide [double barrier methods]), and willing and able to continue contraception for 1 month after the last administration of IMP. Women using oral contraception must have started using it at least 2 months prior to screening. Women are not considered to be of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms). Or have had a surgical bilateral oophorectomy (with or without hysterectomy) or bilateral tubal ligation at least six weeks before the screening visit. In case of oophorectomy alone, the reproductive status of the woman should have been confirmed by follow up hormone level assessment. 14. Severe comorbidity (e.g., drug addiction, psychosis, diabetes) 15. Experimental agents must have been discontinued at least 8 weeks prior to screening for a period equivalent to 5 half-lives of the agent (whichever is longer) 16. Any diagnosed nasal conditions including abnormal nasal anatomy, nasal symptoms (i.e. blocked nose, nasal polyps etc.), or having product sprayed in to the nasal cavity prior to drug administration 17. Subject with concurrent disease considered by the investigator to be clinically significant in the context of the study. |
Country | Name | City | State |
---|---|---|---|
Finland | National Institute for Health and Welfare | Helsinki | Uusimaa |
Lead Sponsor | Collaborator |
---|---|
National Institute for Health and Welfare, Finland |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number and proportion of subjects with adverse events | The use of the daily questionnaire / telephone operated (text messages) diary (daily use of sprays, number of doses, gambling expenditure and frequency and possible adverse events) and self-administration of IMP. | Baseline to week 12 - daily | |
Other | Assessment of clinical laboratory parameters - Pregnancy test | The entire study for an individual participant will last 12 weeks. At Screening and week 12 blood pregnancy test and week 6 urine pregnancy test | Screening to Week 6 and 12 | |
Other | Assessment of vital signs - blood pressure, pulse, temperature | The entire study for an individual participant will last 12 weeks. Assessments at baseline, 6 and 12 vital signs ( blood pressure, pulse and temperature) will be assessed. | Baseline to Week 6 and 12 | |
Other | Assessment of body height | The entire study for an individual participant will last 12 weeks. Assessments at the baseline, week 6, and week 12. Body height will be assessed. | Baseline to Week 6 and 12 | |
Other | Assessment of body weight | The entire study for an individual participant will last 12 weeks. Assessment at baseline, 6, and 12 . Body weight will be assessed. | Baseline to Week 6 and 12 | |
Other | Assessment and examination of nasal mucosa | The entire study for an individual participant will last 12 weeks. Assessment at baseline, 6, and 12 nasal mucosa will be assessed using Nasal Irritation Scale (0= normal appearing mucosa, no bleeding to 5= Ulcerated lesions, bleeding with requires medical intervention). Assessment is performed by MD. | Baseline to Week 6 and 12 | |
Other | Assessment of smell test | The entire study for an individual participant will last 12 weeks. Assessments at baseline and week 12 smell will be assessed.Smell test will be conducted at Baseline and Week 12. NIH Toolbox Odour Identification Test: This validated smell identification test uses 'scratch and sniff' technology, and pictures for the multiple-choice options of 9 common smells. It is intended for a rapid research assessment of olfactory ability. | Baseline to Week 12 | |
Primary | The Gambling Symptom Assessment Scale (G-SAS) gambling symptom severity and change during the treatment - assessment | The G-SAS is a 12-item self-rated scale designed to assess gambling symptom severity and change during treatment. The G-SAS is not a diagnostic or screening instrument. Each 12-item scale has a score ranging from 0 - 4 (adjective anchors for 0 and 4 vary for each item). All items ask for an average symptom based on the past 7 days. Items 1 - 4 can be used to assess changes in craving symptoms. Total score ranges from 0 - 48: extreme = 41 - 48, severe = 31 - 40, moderate = 21 - 30, mild = 8 - 20. | Baseline to week, 3, 6, 9 and week 12. | |
Secondary | VAS (gambling craving) | The entire study for an individual participant will last 12 weeks. From baseline to weeks 3,6,9,and 12 craving of gambling will be assessed. | Baseline to Week 3, 6, 9 and 12 | |
Secondary | Gambling severity (PGSI) | The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 severity of gambling will be assessed. | Baseline to Week 6 and 12 | |
Secondary | Gambling severity (DSM-5) | The entire study for an individual participant will last 12 weeks. From baseline to week 6, and 12 severity of gambling will be assessed. | Baseline to Week 6 and 12 | |
Secondary | Gambling problems (NODS) | The entire study for an individual participant will last 12 weeks. From baseline to weeks 3,6,9,and 12 level of gambling problems will be assessed. | Baseline to Week 3, 6, 9 and 12 | |
Secondary | Gambling expenditure and frequency | daily questionnaire / telephone operated (text messages) diary (daily use of sprays, number of doses, gambling expenditure and frequency and possible adverse events) and self-administration of IMP. | Baseline to Week 12 | |
Secondary | Abstinence of gambling (GASS) | The entire study for an individual participant will last 12 weeks. From baseline to weeks 3,6,9,and 12 abstinence of gambling will be assessed. | Baseline to Week 3, 6, 9 and 12 | |
Secondary | Internet use (Internet disorder scale-9 short form) | The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 internet use will be assessed. | Baseline to Week 6 and 12 | |
Secondary | Quality of life (WHO: EUROHIS-8) | The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 quality of life will be assessed. | Baseline to Week 6 and 12 | |
Secondary | Alcohol consumption (AUDIT) | The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 graving of gambling will be assessed. | Baseline to Week 6 and 12 | |
Secondary | Depression (MADRS) | The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 mood will be assessed. | Baseline to Week 6 and 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02590211 -
Poker, Skills and Associated Problems
|
N/A | |
Completed |
NCT02203786 -
D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement
|
Phase 2 | |
Completed |
NCT05051085 -
Feasibility of the Internet-delivered Treatment "SpilleFri" for Patients With Pathological Gambling
|
N/A | |
Completed |
NCT01215357 -
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
|
Phase 2 | |
Terminated |
NCT00245583 -
Topiramate in the Treatment of Pathological Gambling
|
Phase 3 | |
Completed |
NCT04842461 -
Mental Health, Addictions and Biomarkers in High Athletes Performance
|
||
Not yet recruiting |
NCT03280966 -
Effects of Intranasal Naloxone on Gambling Urges in Gambling Disorder
|
Phase 2 | |
Active, not recruiting |
NCT01743092 -
Testing Resources: Manual and Webinar Guided Treatment vs. Manual Guided Treatment
|
N/A | |
Active, not recruiting |
NCT01528982 -
Susceptibility to Pathological Gambling
|
N/A | |
Terminated |
NCT00211822 -
Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)
|
N/A | |
Completed |
NCT01381250 -
Effects of Internet-based Treatment of Pathological Gambling
|
N/A | |
Completed |
NCT05506384 -
Treatment Study for Problematic Gaming and Gambling
|
N/A | |
Enrolling by invitation |
NCT03464838 -
Effects of Transcranial Direct Current Stimulation (tDCS) in Gambling Disorder
|
N/A | |
Terminated |
NCT01560351 -
Repeated Low-frequency Transcranial Magnetic Stimulation Reduces Cue-induced Craving: a Randomized, Prospective, Double-blind, Sham-controlled, Cross-over Study
|
N/A | |
Completed |
NCT00580567 -
Impulsivity in Pathological Gambling
|
N/A | |
Completed |
NCT02240485 -
Integrative Couple Treatment for Pathological Gambling
|
N/A | |
Withdrawn |
NCT01340274 -
Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling
|
Phase 2 | |
Recruiting |
NCT02491996 -
The Efficacy of Therapy Focused on Desire-satisfaction for Disordered Gamblers
|
N/A | |
Recruiting |
NCT01154712 -
Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling
|
Phase 1 | |
Completed |
NCT00927563 -
Tolcapone Treatment of Pathological Gambling
|
Phase 2 |